A clinical study of Tyvyt® (sintilimab injection) in combination with STP705 (cotsiranib) for treatment of advanced cancers

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 13 Feb 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

10 Feb 2020 According to an Sirnaomics media release, company anticipate the start of our clinical study for HCC in the second half of 2020.
10 Jan 2020 New trial record
07 Jan 2020 According to an Sirnaomics media release, the company and Innovent Biologics, Inc. jointly announced today that they have entered a strategic collaboration to conduct clinical studies, using Innovent's antibody drug Tyvyt(sintilimab injection) and Sirnaomics's RNAi drug candidate STP705 (cotsiranib), for combination treatment in advanced cancers, such as Hepatocellular Carcinomas (HCC), with high unmet need in the US.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com